Karla L Miller 1 , * , Fidel Alfaro-Almagro 1 , Neal K Bangerter 2 , David L Thomas 3 , Essa Yacoub 4 , Junqian Xu 5 , Andreas J Bartsch 6 , Saad Jbabdi 1 , Stamatios N Sotiropoulos 1 , Jesper LR Andersson 1 , Ludovica Griffanti 1 , Gwenaëlle Douaud 1 , Thomas W Okell 1 , Peter Weale 7 , Iulius Dragonu 7 , Steve Garratt 8 , Sarah Hudson 8 , Rory Collins 8 , 9 , Mark Jenkinson 1 , Paul M Matthews 10 , Stephen M Smith 1
19 September 2016
Medical imaging has enormous potential for early disease prediction, but is impeded by the difficulty and expense of acquiring datasets prior to symptom onset. UK Biobank aims to address this problem directly by acquiring high quality, consistently acquired imaging data from 100,000 predominantly healthy participants, with health outcomes tracked over coming decades. The brain imaging includes structural, diffusion and functional modalities. Along with body and cardiac imaging, genetics, lifestyle measures, biological phenotyping and health records, this is expected to enable discovery of imaging markers of a broad range of diseases at their earliest stages, as well as provide unique insight into disease mechanisms. We describe UK Biobank brain imaging, and present results derived from the first 5,000 participants’ data release. Although that covers just 5% of the ultimate cohort, it already yields a rich range of associations between brain imaging and other measures collected by UK Biobank.